Emerging trends and resistance patterns of extended-spectrum beta-lactamases producing Enterobacteriaceae: an epidemiological insight from Ibn Tofail hospital in Marrakesh, Morocco
DOI:
https://doi.org/10.3855/jidc.21200Keywords:
Enterobacteriaceae, expanded-spectrum, beta-lactamases, epidemiology, antibiotics, resistanceAbstract
Introduction: The epidemiology of ESBL infection varies widely from one region to another and rapidly evolves across hospital and community boundaries. Therefore, obtaining an updated local picture of the epidemiology of ESBL-producing microorganisms and analyzing trends in their dissemination is essential. The main aim of this study was to assess the prevalence and the antibiotic resistance profiles of ESBL-producing Enterobacteriaceae (ESBL-E) at Ibn Tofail Hospital in Marrakesh.
Methodology: To our knowledge, the present study is the first to conduct a descriptive analysis from January 1, 2010, to December 31, 2022, including all ESBL-E strains isolated in the microbiology laboratory. Antimicrobial susceptibility testing was determined using the standardized Kirby-Bauer disk diffusion method on Mueller-Hinton agar. The double-disc synergy test confirmed the presence of ESBL.
Results: Among 3672 Enterobacteriaceae strains isolated, 20% were ESBL producers. Klebsiella pneumoniae accounted for 45.9% of ESBL-E, followed by Escherichia coli (25.3%) and Enterobacter cloacae (12.8%). The surgical and intensive care units were most affected. Urine samples were the most common source (42.4%). ESBL-E strains exhibited high resistance to tobramycin (80.3%), gentamicin (72.9%), and ciprofloxacin (73.7%), but maintained sensitivity to imipenem (15.6% resistance) and amikacin (21.9%). Significant differences were detected between non-ESBL and ESBL regarding all tested antibiotics. Male patients were significantly more affected by ESBL-E than females.
Conclusions: The increasing incidence of ESBL-E has become a significant concern. Monitoring their epidemiological and resistance profiles is crucial for guiding antibiotic therapy and preventing the development of further resistant strains.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Fatima zohra MADICH, Mohamed Yassir Errahmani, Loubna AIT SAID, Karima WARDA, Kawtar ZAHLANE

This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).

